## Supplementary Figures:


$\rightarrow$ HRAS, EPASl and MAX somatic study (18 adrenergic plus 39 noradrenergic plus 41 not available/no secretion)
$\rightarrow$ RET somatic study ( 18 adrenergic plus 41 not available/no secretion)
$\rightarrow$ VHL study ( 39 noradrenergic plus 41 not available/no secretion)
$\rightarrow$ SDHB study (1 tumor with negative SDHB-IHC plus 3 FFPE umors with SDHB-IHC not evaluable plus 19 frozen tumors without adrenergic secretion.

## 43 Somatic mutations



Figure SL. Details summarizing the steps of the genetic workflow study.

Figure 2:


